Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MT-DADMe‑ImmA is a synthetic small molecule and a transition-state analogue inhibitor of methylthioadenosine phosphorylase (MTAP). It is structurally related to Immucillin analogues and designed to mimic the transition state of the enzymatic reaction catalyzed by MTAP. By inhibiting this enzyme, it interferes with polyamine biosynthesis and methionine salvage pathways. This compound has been studied primarily as a biochemical tool for probing enzyme mechanisms and as a potential lead in anti-cancer drug development due to its ability to disrupt tumor cell metabolism dependent on MTAP activity. Its primary use remains experimental in nature.[1][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MT-DADMe-ImmA.